Affimed N.V. (AFMDQ)

Market Cap	1.31M
Revenue (ttm)	6.29M
Net Income (ttm)	-78.04M
Shares Out	16.39M
EPS (ttm)	-5.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	103,669
Average Volume	49,043,451
Open	0.0690
Previous Close	0.0800
Day's Range	0.0680 - 0.0999
52-Week Range	0.0180 - 8.9500
Beta	1.53
RSI	33.57
Earnings Date	May 22, 2025

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatme...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 76
• Stock Exchange: OTCMKTS
• Ticker Symbol: AFMDQ

Financial Performance

In 2023, Affimed's revenue was 13.91 million, a decrease of -67.39% compared to the previous year's 42.67 million. Losses were -105.94 million, 23.2% more than in 2022.

Financial numbers in EUR